Veraxa Biotech (NASDAQ: VRXA), a developer of novel cancer therapies, announced the expansion of its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support the planned growth of the company’s R&D team, installation of new laboratory equipment, and completion of infrastructure needed to advance future development activities.
The expansion aligns with Veraxa’s efforts to advance its growing portfolio of proprietary and partnered oncology programs from discovery-stage research toward early clinical development. The company’s pipeline is centered on its BiTAC platform, including BiTAC-TCE and BiTAC-ADC candidates, which are designed to enable tumor-restricted activation of cancer therapies through the use of complementary precursor molecules. This approach aims to improve therapeutic efficacy while reducing systemic toxicity, a significant challenge in oncology drug development.
Veraxa was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, Veraxa is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
The expansion in Heidelberg is a strategic move to accommodate the company’s growing team and enhance its research capabilities. By increasing its laboratory space, Veraxa can install state-of-the-art equipment and infrastructure necessary for the complex processes involved in developing cancer therapies. This investment signals confidence in the company’s pipeline and its potential to address unmet medical needs in oncology.
For more details, the full press release is available at https://ibn.fm/n3t6U. The latest news and updates relating to VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the company’s filings with the SEC. Investors should not place undue reliance on these forward-looking statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law.
